Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13D/A

Arcellx Inc.

Beneficial Ownership Report

Filed Feb 24, 2026Accepted Feb 24, 2026, 7:07 PM ESTFiling CIK 1613689Accession 0001193125-26-067840
Share

Structured filing — SCHEDULE 13D/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Arcellx, Inc.
Company CIK
0001786205
Street
800 Bridge Parkway
City
Redwood City
State / country code
CA
Postal code
94065

Statement details

Amendment number
2
Security class
Common stock, par value $0.001 per share
Event date
02/22/2026
Previously filed indication
false

Authorized notification person 1

Name
Rami Elghandour
Phone
(240) 327-0630
Street
c/o Arcellx, Inc.
Street (continued)
800 Bridge Parkway
City
Redwood City
State / country code
CA
Postal code
94065

Reporting person 1

Name
Rami Elghandour
Reporting person CIK
0001613689
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
PF
Legal proceedings indication
N
Aggregate amount owned
3,938,771
Percent of class
6.4
Sole voting power
3,522,271
Shared voting power
416,500
Sole dispositive power
3,522,271
Shared dispositive power
416,500
Aggregate excludes certain shares
N
Comments
(1) Row 7, 9 and 11: Consists of (i) 365,967 shares of common stock held directly by the Reporting Person, (ii) 2,346,202 shares of common stock issuable pursuant to options held directly by the Reporting Person exercisable within 60 days of February 22, 2026, and (iii) 810,102 shares of common stock issuable pursuant to options held by a grantor-retained annuity trust of the Reporting Person exercisable within 60 days of February 22, 2026. (2) Row 8, 10 and 11: Consists of (i) 218,500 shares of common stock held by a spousal lifetime access non-grantor trust of which the Reporting Person is a beneficiary and for which the Reporting Person may be deemed to continue to have beneficial ownership, and (iii) 198,000 shares of common stock held by a spousal lifetime access non-grantor trust of which the Reporting Person's spouse is the beneficiary and for which the Reporting Person may be deemed to continue to have beneficial ownership. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any, and this Schedule shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for any other purpose. (3) Row 13: Based on the quotient obtained by dividing (a) the aggregate number of shares of common stock beneficially owned by the Reporting Person by (b) the sum of (i) 58,464,222 shares of common stock outstanding as of February 19, 2026, based on information provided to the Reporting Person by the Issuer, (ii) 2,346,202 shares of common stock issuable pursuant to options held directly by the Reporting Person exercisable within 60 days of February 22, 2026, and (iii) 810,102 shares of common stock issuable pursuant to options held by a grantor-retained annuity trust of the Reporting Person exercisable within 60 days of February 22, 2026. The aggregate number of shares of common stock beneficially owned by the Reporting Person as set forth in "(ii)" and "(iii)" of this footnote are treated as outstanding shares of common stock only for the purpose of computing the percentage ownership of the Reporting Person.

Item 1

Issuer

Arcellx, Inc.

Security title

Common stock, par value $0.001 per share

Principal address

Comment

This Amendment No. 2 ("Amendment No. 2") amends and supplements the Statement of Beneficial Ownership on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") by Rami Elghandour on November 8, 2024 as amended on February 27, 2025 (as amended, the "Schedule 13D") with respect to shares of common stock, par value $0.001 per share ("common stock"), of Arcellx, Inc. (the "Issuer"). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Schedule 13D, which remains unchanged. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.

Item 4

Purpose of transaction

Merger Agreement On February 22, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). The Merger Agreement provides for the acquisition of the Issuer by Parent in a two step transaction, consisting of a tender offer followed by a subsequent merger of Purchaser with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein, Purchaser will commence a tender offer (the "Offer"), to acquire all of the Issuer's issued and outstanding shares of common stock (the "Shares"), other than any Shares owned immediately prior to the effective time of the Merger by the Issuer (including shares held in the Issuer's treasury) and any Shares owned both as of the date of the commencement of the Offer and immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or indirect wholly owned subsidiary of Parent, for (x) $115.00 per Share, net to the seller in cash, without interest and subject to any required withholding of taxes (the "Closing Amount"), and (y) one contractual contingent value right (a "CVR"), which will represent the right to receive one contingent milestone payment of $5.00 per CVR, in cash, without interest and subject to any required withholding of taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), to be entered into with a rights agent selected by Parent and reasonably acceptable to the Issuer (the Closing Amount plus one (1) CVR together, the "Offer Price"). The Offer will initially remain open for a minimum of 20 business days from the date of commencement of the Offer, subject to extension pursuant to the terms of the Merger Agreement. At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share, other than any Shares (i) owned immediately prior to the Effective Time by the Issuer, Parent, Purchaser or any other wholly owned subsidiary of Parent (the "Excluded Shares"), (ii) irrevocably accepted for purchase pursuant to the Offer, or (iii) for which holders have demanded their rights to be paid the fair value of such Share in accordance with Section 262 of the Delaware General Corporation Law, will be converted into the right to receive (x) the Closing Amount in cash plus (y) one (1) CVR (the "Merger Consideration"), in each case without interest (except, in the case of the CVR, deemed interest for tax purposes, as applicable) and subject to any required withholding taxes. At the Effective Time, each option to purchase Shares (each, a "Company Option") that is then outstanding and unexercised, whether or not vested, and which has a per share exercise price that is less than the Merger Consideration, will be automatically canceled and converted into the right to receive (x) a lump-sum cash payment equal to (i) the excess (if any) of (a) the Closing Amount over (b) the per Share exercise price subject to such Company Option, multiplied by (ii) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (y) one (1) CVR for each Share subject to such Company Option immediately prior to the Effective Time. At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested, and which has a per share exercise price that is equal to or greater than the Closing Amount, will be canceled without additional consideration. At the Effective Time, each award of restricted stock units with respect to Shares (each, a "Company RSU") that is then outstanding, whether or not vested, will be automatically canceled and converted into the right to receive (x) a lump-sum cash payment equal to the product, rounded to the nearest cent, of (i) the Closing Payment and (ii) the number of Shares subject to such Company RSU immediately prior to the Effective Time (with the number of Shares underlying any Company RSUs that are subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof) and (y) one (1) CVR for each Share subject to such Company RSU immediately prior to the Effective Time. The foregoing description of the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, a copy which is filed as Exhibit 2.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on February 23, 2026. Tender and Support Agreements On February 22, 2026, in connection with the execution and delivery of the Merger Agreement, the Reporting Person and certain other parties (collectively, the "Support Stockholders"), solely in their respective capacities as stockholders of the Issuer, each entered into a tender and support agreement (collectively, the "Support Agreements") with Parent and Purchaser, pursuant to which each Support Stockholder agreed, among other things, (i) to tender all of the Shares held by such Support Stockholder in the Offer, subject to certain exceptions (including the valid termination of the Merger Agreement), (ii) to, if applicable, vote all of such Support Stockholder's Shares in favor of the Merger, and (iii) to certain other restrictions on its ability to take actions with respect to the Issuer and its Shares. The Support Agreements will terminate upon the earliest of (i) the date and time upon which the Merger Agreement is validly terminated in accordance with its terms, and (ii) the date and time upon which the Merger becomes effective. The foregoing description of the Support Agreements does not purport to be complete and is qualified in its entirely by reference to the form of Support Agreement, which is filed as Exhibit 5 to this Amendment No. 2 and is incorporated herein by reference.

Item 6

Contracts and arrangements

(a) Description of contracts, arrangements, understandings, or relationships Item 6 of the Schedule 13D is hereby amended and supplemented as follows: On February 22, 2026, the Reporting Person entered into the Support Agreement described in Item 4 of Amendment No. 2, the description of which is incorporated by reference herein.

Item 7

Filed exhibits

Item 7 of the Schedule 13D is hereby supplemented to add the following exhibit: Form of Tender and Support Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed by the Issuer with the SEC on February 23, 2026).

Signature 1

Reporting person
Rami Elghandour
Signed
/s/ Rami Elghandour
Title
Rami Elghandour
Date
02/24/2026

Company context

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by Vestal Point Capital, LP regarding Arcellx, Inc.May 15, 2026
  2. 15-12G filingMay 8, 2026
  3. 4 filingApr 28, 2026
  4. 4 filingApr 28, 2026
  5. 4 filingApr 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.